Dr. Kato is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3855 Health Sciences Dr
La Jolla, CA 92093Phone+1 858-822-2372Fax+1 619-543-6645
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2007 - 2010
OtherClass of 2005
Certifications & Licensure
CA State Medical License 2010 - 2025
TX State Medical License 2015 - 2016- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Start of enrollment: 2016 Aug 31
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Start of enrollment: 2018 May 02
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 3 citationsIf it's a target, it's a pan-cancer target: Tissue is not the issue.Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Cancer Treatment Reviews. 2024-04-01 - 24 citationsThe paradox of cancer genes in non-malignant conditions: implications for precision medicineJacob J. Adashek, Shumei Kato, Scott M. Lippman, Razelle Kurzrock
Genome Medicine. 2020-02-17 - 2 citationsAt the right dose: personalised (N-of-1) dosing for precision oncology.Mina Nikanjam, Shumei Kato, Jason K Sicklick, Razelle Kurzrock
European Journal of Cancer. 2023-11-01
Journal Articles
- Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric AdenocarcinomaLawrence Leichman, Jason K Sicklick, Shumei Kato, Kaitlyn Kelly, Scott M Lippman, Clinical Cancer Research
Lectures
- A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients.2019 ASCO Annual Meeting - 6/1/2019
- PDL1 landscape in checkpoint inhibitor ineligible patients by IHC and cfRNA.2019 ASCO Annual Meeting - 6/1/2019
- RAS alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Breast Cancer Drug Could Help Treat Rare Appendix CancerOctober 20th, 2024- Breast Cancer Drug Offers New Hope for Treating Rare Appendix CancerOctober 18th, 2024
- Study: Breast Cancer Drug Shows Potential for Rare Appendix CancerOctober 16th, 2024
- Join now to see all
Other Languages
- Japanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
